In Vitro Activity of Ceftolozane/Tazobactam vs Nonfermenting, Gram-Negative Cystic Fibrosis Isolates-Reference-Cited by-同舟云学术

In Vitro Activity of Ceftolozane/Tazobactam vs Nonfermenting, Gram-Negative Cystic Fibrosis Isolates

Published:2018-07-01 Issue:7 Volume:5 Page:
ISSN:2328-8957
Container-title:Open Forum Infectious Diseases
language:en
Short-container-title:

Author:

Forrester Jeanne B¹^ORCID,Steed Lisa L²,Santevecchi Barbara A¹,Flume Patrick²,Palmer-Long Gloria E²,Bosso John A¹²

Affiliation:

1. College of Pharmacy, Medical University of South Carolina, Charleston, South Carolina

2. College of Medicine, Medical University of South Carolina, Charleston, South Carolina

Abstract

Abstract Ceftolozane/tazobactam (C/T) was tested and compared against 93 nonfermenting, Gram-negative clinical isolates from cystic fibrosis specimens. Based on current breakpoints for intra-abdominal and urinary tract infections (which may not be appropriate for pulmonary infections), C/T was found to be the most active agent against P. aeruginosa (95.7% susceptible), followed by piperacillin/tazobactam (89.4% susceptible). For other Gram-negative pathogens included, C/T had varying activity.

Funder

Merck & Co., Inc

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Oncology

Link

http://academic.oup.com/ofid/article-pdf/5/7/ofy158/33591222/ofy158.pdf

Reference20 articles.

1. The problems of antibiotic resistance in cystic fibrosis and solutions;López-Causapé;Expert Rev Respir Med,2015

2. Of Pseudomonas, porins, pumps and carbapenems;Livermore;J Antimicrob Chemother,2001

3. Ceftolozane/tazobactam: a new cephalosporin and β-lactamase inhibitor combination;Sucher;Ann Pharmacother,2015